Lymphoplasmacytic lymphoma
MONDO:0000432A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.
Also known as: Immunocytoma, lymphoplasmacytic type, lymphoma, lymphoplasmacytic, malignant, lymphoma, plasmacytic, lymphoplasmacytic lymphoma, lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia), lymphoplasmacytoid lymphoma
2067 clinical trials for this condition and its sub-types, 44 tagged with Lymphoplasmacytic lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Lymphoplasmacytic lymphoma
-
Waldenstrom macroglobulinemia 136 trials
2 sub-types
- Macroglobulinemia, Waldenstrom, 1 2 trials
- Macroglobulinemia, Waldenstrom, 2 0 trials
-
Cancer vaccine trial tests immune system boost for rare lymphoma
Disease control CompletedThis phase 1 trial tested a personalized DNA vaccine in 9 patients with a rare, slow-growing blood cancer called lymphoplasmacytic lymphoma. The vaccine was made from each patient's own cancer cells and designed to help the immune system recognize and attack the cancer. The main …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Immunotherapy combo shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis phase 2 trial tested the immunotherapy drug pembrolizumab (Keytruda) alone or combined with idelalisib or ibrutinib in 65 patients with chronic lymphocytic leukemia (CLL) or low-grade B-cell non-Hodgkin lymphoma (NHL) that had returned or stopped responding to treatment. The…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Early trial explores new drug for blood cancers in japanese patients
Disease control CompletedThis early-phase study tested a new drug called nemtabrutinib in 7 Japanese adults with certain blood cancers (like chronic lymphocytic leukemia). The main goals were to check the drug's safety and how the body processes it. Researchers looked for side effects and measured drug l…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Half-Matched stem cell transplant shows promise for older blood cancer patients
Disease control CompletedThis study tested a stem cell transplant from half-matched (haploidentical) family donors for 34 people with various blood cancers. Patients received a reduced-intensity conditioning regimen of fludarabine, melphalan, and total body irradiation before the transplant. The goal was…
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug combo aims to stall lymphoma without chemo
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug copanlisib to the standard antibody rituximab helps people with relapsed indolent B-cell non-Hodgkin's lymphoma live longer without their cancer getting worse. The study included 458 adults who had already received at lea…
Phase 3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
CAR-T therapy Follow-Up study shows no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatme…
Phase 1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC